Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | BCL6 | P41182 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31153803 | 0.85 | CSNK2A1 (0.39) | CSNK2A1CDK2 | |
| SCHEMBL19742592 | 0.80 | CSNK2A1 (0.50) | CSNK2A1CDK2BCL6CSNK2A2 | |
| SCHEMBL19742601 | 0.78 | KDM5A (0.44) | CSNK2A1CDK2 | |
| SCHEMBL19742642 | 0.78 | CSNK2A1 (0.51) | CSNK2A1CDK2BCL6CSNK2A2CSNK2B | |
| SCHEMBL1486116 | 0.77 | CSNK2B (0.50) | CSNK2A1CSNK2B | |
| SCHEMBL31153817 | 0.75 | CDK2 (0.46) | CSNK2A1CDK2 | |
| SCHEMBL6890102 | 0.72 | CSNK2A1 (0.52) | CSNK2A1CDK2GSK3B | |
| SCHEMBL1487735 | 0.70 | CDK9 (0.43) | CDK2 | |
| SCHEMBL31064465 | 0.70 | CDK2 (0.41) | CDK2 | |
| SCHEMBL1934329 | 0.69 | CSNK2B (0.38) | CSNK2A1CSNK2BGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | CSNK2A1 2/4885CDK2 14/4885BCL6 2482/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | CSNK2A1 2/4885CDK2 14/4885BCL6 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.